Satellos Bioscience Inc. (MSCL.V)

0.5500 +0.1000 (+22.22%) As of 11:51AM EDT. Market open.

Satellos Bioscience Inc.

65 Front Street East
Suite 201
Toronto, ON M5E 1B5
Canada
647 660 1780
https://satellos.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Francis Gleeson B.B.A. M.B.A	Co-Founder, CEO, Pres & Director	233.33k	N/A	1955
Dr. Michael A. Rudnicki Ph.D.	Co-Founder & Chief Scientific Officer	98k	N/A	1961
Mr. Warren Whitehead C.M.A., CPA	Chief Financial Officer	46.13k	N/A	1952
Mr. William Wasyl Jarosz	Exec. Director	162.27k	N/A	1956
Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA	Strategic Advisor	44.48k	N/A	1960
Dr. Philip Lambert M.A., Ph.D.	Chief Technology Officer	N/A	N/A	1968
Mr. J. Robert Hall CFA	VP of Fin. & Admin.	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

Corporate Governance

Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.